Clinical Trial Update: Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating cabergoline for prevention of ovarian hyperstimulation syndrome (OHSS) in IVF cycles completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Hyperstimulation Syndrome

Drugs mentioned

• CABERGOLINE (CABERGOLINE)

Snippet

Sponsor: KK Women's and Children's Hospital | Conditions: Ovarian Hyperstimulation Syndrome | Phase 3 | Status: COMPLETED